Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) recurrence after liver transplantation occurs in approximately 20% of patients. Most of these patients use immunosuppressant drugs. Meanwhile, patients with HCC recurrence are frequently treated with the small molecule kinase inhibitor (SMKI) sorafenib. However, sorafe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussaarts, Koen G. A. M., van Doorn, Leni, Bins, Sander, Sprengers, Dave, de Bruijn, Peter, van Leeuwen, Roelof W. F., Koolen, Stijn L. W., van Gelder, Teun, Mathijssen, Ron H. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826978/
https://www.ncbi.nlm.nih.gov/pubmed/33435321
http://dx.doi.org/10.3390/ph14010046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826978/
https://www.ncbi.nlm.nih.gov/pubmed/33435321
http://dx.doi.org/10.3390/ph14010046

Ejemplares similares